



**FRANKLIN
TEMPLETON**

Franklin Templeton Investment Funds

Franklin Biotechnology Discovery Fund

Sector Equity
30.04.2024

Fund Fact Sheet

Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	1.63 billion
Fund Inception Date	03.04.2000
Number of Issuers	86
Benchmark	NASDAQ Biotechnology Index
Morningstar Category™	Sector Equity Biotechnology

Minimum Investment

Share Class	Initial	Subsequent
A (acc) USD	USD 1,000	USD 500
A (acc) SGD	SGD 1,000	SGD 500

Summary of Investment Objective

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

Fund Management

Evan McCulloch, CFA: United States
Wendy Lam, PhD: United States
Akiva Felt: United States

Ratings - A (acc) USD

Overall Morningstar Rating™: ★★★★★

Asset Allocation


	%
Equity	99.11
Cash & Cash Equivalents	0.89

Performance

Past performance does not predict future returns.

Performance over 5 Years in Share Class Currency (%)

■ Franklin Biotechnology Discovery Fund A ■ NASDAQ Biotechnology Index (acc) USD



Performance in Share Class Currency (%)

	Cumulative					Annualised	
	1 Mth	3 Mths	YTD	1 Yr	Since Incept	3 Yrs	Since Incept
A (acc) USD	-7.01	-0.82	4.10	16.98	298.07	-2.67	5.91
After Sales Charge*	-11.66	-5.78	-1.10	11.13	278.17	-4.32	5.68
Benchmark in USD	-6.04	-5.08	-4.77	-0.60	290.72	-5.07	5.82
A (acc) SGD	-5.99	0.94	7.67	19.68	295.76	-1.85	8.69
After Sales Charge*	-10.69	-4.10	2.29	13.70	275.97	-3.51	8.35
Benchmark in SGD	-4.94	-3.39	-1.49	1.69	350.55	-4.26	9.54

Top Ten Holdings (% of Total)

Issuer Name	%
AMGEN INC	7.09
REGENERON PHARMACEUTICALS INC	6.35
VERTEX PHARMACEUTICALS INC	5.40
ASCENDIS PHARMA A/S	4.08
ASTRAZENECA PLC	3.70
BIOGEN INC	3.15
GILEAD SCIENCES INC	3.00
INTRA-CELLULAR THERAPIES INC	2.91
JAZZ PHARMACEUTICALS PLC	2.70
NEUROCRINE BIOSCIENCES INC	2.65

Share Class Information (For a full list of available share classes, please visit www.franklintempleton.com.sg.)

Share Class	Incept Date	NAV	TER (%)	Fees	
				Max. Sales Charge (%)	Max. Annual Charge (%)
A (acc) USD	03.04.2000	USD 39.81	1.82	5.00	1.50
A (acc) SGD	25.10.2007	SGD 39.58	1.82	5.00	1.50

Additional Share Class Information

Share Class	Incept Date	Subscription Type	Dividends	Fund Identifiers	
			Frequency	Bloomberg ID	ISIN
A (acc) USD	03.04.2000	Cash	N/A	TEMBDAI LX	LU0109394709

Templeton Asset Management Ltd

7 Temasek Boulevard #38-03

Suntec Tower One

Singapore 038987

Phone

(65) 6241 2662

Share Class	Incept Date	Subscription Type	Dividends	Fund Identifiers	
			Frequency	Bloomberg ID	ISIN
A (acc) SGD	25.10.2007	Cash/SRS	N/A	TEBTASG LX	LU0320765992

Composition of Fund

Market Capitalisation Breakdown in

USD	% of Equity
<2.0 Billion	30.46
2.0-5.0 Billion	15.74
5.0-10.0 Billion	12.69
10.0-25.0 Billion	9.94
25.0-50.0 Billion	3.18
>50.0 Billion	26.58
N/A	1.41

What Are the Key Risks?

The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: liquidity risk, securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the "Risk Considerations" section of the Fund in the current prospectus of Franklin Templeton Investment Funds.

Important Information

This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

This document is for information only and does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any research and analysis contained in this document has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. Any views expressed are the views of the fund manager as of the date of this document and do not constitute investment advice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole.

There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from the use of any information, opinion or estimate herein.

The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested.

Past performance is not necessarily indicative nor a guarantee of future performance of the Fund. Subscriptions may only be made on the basis of the most recent Prospectus and Product Highlights Sheet which is available at Templeton Asset Management Ltd or authorised distributors of the Fund. Potential investors should read the details of the Prospectus and Product Highlights Sheet before deciding to subscribe for or purchase the Fund. This shall not be construed as the making of any offer or invitation to anyone in any jurisdiction in which such offer is not authorised or in which the person making such offer is not qualified to do so or to anyone to whom it is unlawful to make such an offer. In particular, the Fund is not available to U.S. Persons and Canadian residents.

Investors may wish to seek advice from a financial adviser before making a commitment to invest in shares of the Fund. In the event an investor chooses not to seek advice from a financial adviser, he/she should consider whether the Fund is suitable for him/her.

Franklin Biotechnology Discovery Fund is/are sub-fund(s) of Franklin Templeton Investment Funds ("FTIF"), a Luxembourg registered SICAV.

Important Information (continued)

In addition, a summary of investor rights is available from <https://www.franklintempleton.com.sg/summary-of-investors-rights.pdf>. The summary is available in English. The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.

Copyright© 2024. Franklin Templeton. All Rights Reserved. Issued by Templeton Asset Management Ltd. Registration No.(UEN) 199205211E.

Performance: Performance details provided are in the share class currency, based on NAV-NAV and include reinvested dividends. Performances of different share classes will vary. Please refer to the Fund Manager for more information.

References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Charges: The charges are the fees the fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by the Fund, which will impact on the overall return of the Fund. Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Ratings: © Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

After Sales Charge*: Calculated based on initial sales charge of 5%; or 0% for Money Market Funds.

Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended and readers should not assume that investment in the securities listed was or will be profitable. All portfolio holdings are subject to change.